Utah’s Expanded Right to Try Law: A Signal for Radiopharmaceutical Innovation

Published May 28, 2026

The State of Utah just made it easier for patients with serious cancers to access investigational therapies. In doing so, Utah added another data point to a consistent pattern: the state has repeatedly chosen to prioritize patient access and back it with real resources.

Governor Spencer Cox signed Senate Bill 222 (SB 222) in March 2026, expanding the state’s Right to Try law, effective May 6. For radiopharmaceutical companies, SB 222 is the latest in a series of deliberate choices, from economic development tax incentives (link, link) to a $4 million workforce investment, that signal Utah has decided innovation in this space is worth backing, not just welcoming.

What It Means for Radiopharmaceutical Companies

The expanded eligibility is particularly relevant for radiopharmaceuticals, where the target patient population — aggressive or late-stage cancers — may no longer need to clear a terminal threshold to seek access. That earlier entry point could increase the volume of compassionate-use requests companies receive and generate real-world data that informs physician awareness and commercial strategy over time.

Right to Try is not a revenue pathway. Participation is voluntary, supply diversion requires careful management, and trial enrollment must be protected. That said, for companies with an established production platform and clear internal policies, the law creates an option to build early relationships with clinicians and patients that may matter downstream.

The annual reporting requirement is manageable and useful. Here, Utah seeks to thread the needle: reducing friction for innovation without abandoning accountability. Even high-level, aggregated outcome data can build the kind of evidence base policymakers and health systems rely on when evaluating emerging therapies.

For companies evaluating where to locate research, production, or early-access programs, the regulatory clarity and openness provided by SB 222 to emerging modalities is a real differentiator in site-selection decisions. The law also works in concert with federal oversight, by tying eligibility to FDA Phase 1 completion and active investigations.

Developed by the Wasatch Group, Lake Park is purpose-built to integrate the full medical ecosystem — from research and production through clinical application — with cancer treatment as its organizing focus.

“At the Lake Park Medical Innovation Campus, we’re building a vibrant new home for the health care community to innovate,” said John Dahlstrom, executive vice president of Wasatch Property Management. “Collaboration is built into the heart of all we are doing. We are actively working to attract complementary companies to the campus to contribute to something larger than any one company could accomplish alone.”

The anchor tenant of the campus is Nusano, a medical radioisotope producer bringing a first-of-its-kind production platform online to supply a rapidly growing cancer of cancer drugs known as radiotherapeutics. Its 190,000-square-foot facility, coming online this year, will have the capacity to produce up to 12 different radioisotopes simultaneously, giving drug developers access to supply that has historically been difficult to secure at the scale and diversity needed for R&D and clinical programs.

That production infrastructure is already attracting the surrounding ecosystem. Ratio Therapeutics, a radiopharmaceutical drug developer, and Summit Bioservices, a biostorage provider, have both located to the area — drawn in part by proximity to Nusano’s supply platform.